Talphera Inc (TLPH) Stock Price, Quote & News

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 650 216 3500

Website: talphera.com

Address:

1850 Gateway Drive, Suite 175, San Mateo, United States

bobmoney Dec. 25 at 2:44 PM

$TLPH Talphera's late Phase 3 underway at some of the Best medical sites in the USA... stay tuned... TLPH's Niyad would be the 1st FDA approved...

0 · Reply

LettuceLeverage Dec. 25 at 9:34 AM

$TLPH Risk premia compress only when proof accumulates, with macro volatility magnifying operational missteps. Momentum turns durable only after multiple confirmations.

0 · Reply

bobmoney Dec. 24 at 9:00 PM

$TLPH $10 plus if Niyad is FDA approved... my hope...

0 · Reply

bobmoney Dec. 24 at 9:00 PM

$TLPH Merry Christmas! May we see TLPH's Niyad FDA approved in 2026... & a stock price over $10... !

0 · Reply

Aawilliam2003 Dec. 24 at 7:56 PM

$TLPH if this gets acquired it will be for about $7. Run up to that

0 · Reply

bobmoney Dec. 24 at 4:03 PM

$TLPH Niyad needed in the USA ASAP...fact

0 · Reply

bobmoney Dec. 24 at 4:01 PM

$TLPH nazz...thinking to bet another 5,000 shares... think news any day... !

0 · Reply

bobmoney Dec. 24 at 3:26 PM

$TLPH look at OMER... FDA approval... believers won... :-) Niyad next up ? :-)))

0 · Reply

nazzangr Dec. 24 at 3:16 PM

$TLPH if you have strong beliefs keep loading up if you can….. Certainly no news will be given about compassion use til next year. Maybe 35 patient updates? But very low chance. Can wait to see where SP bottoms out or keep adding. Wish i had some cash!

0 · Reply

bobmoney Dec. 24 at 3:15 PM

$TLPH $CRMD happy holidays & Merry Christmas... CRMD & TLPH 2026 collaboration that will make (if Niyad is FDA approved in 2026) Niyad a game changer in Extracorporeal Circuit anticoagulant... !

0 · Reply

Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

CRMD

Nov 5, 2025, 4:05 PM EST - 7 weeks ago

Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025

Oct 21, 2025, 8:30 AM EDT - 2 months ago

Talphera Announces the Appointment of Joe Todisco to Board of Directors

Sep 8, 2025, 8:30 AM EDT - 3 months ago

CorMedix Announces Strategic Minority Investment in Talphera

CRMD

Sep 8, 2025, 8:30 AM EDT - 3 months ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CRMD

Aug 25, 2025, 8:30 AM EDT - 4 months ago

Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

Aug 14, 2025, 9:10 PM EDT - 4 months ago

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 4:05 PM EDT - 4 months ago

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:35 PM EDT - 4 months ago

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

May 14, 2025, 9:01 PM EDT - 8 months ago

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 8 months ago

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 8 months ago

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Mar 31, 2025, 6:33 PM EDT - 9 months ago

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:05 PM EDT - 9 months ago

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 8:30 AM EDT - 9 months ago

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Mar 26, 2025, 4:38 PM EDT - 9 months ago

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Jan 14, 2025, 8:30 AM EST - 1 year ago

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Nov 13, 2024, 6:43 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 6, 2024, 4:05 PM EST - 1 year ago

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Oct 8, 2024, 4:54 PM EDT - 1 year ago

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 5, 2024, 4:15 PM EDT - 1 year ago

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 19, 2024, 8:30 AM EDT - 1 year ago

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Aug 14, 2024, 6:39 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

May 20, 2024, 5:25 PM EDT - 1 year ago

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 16, 2024, 5:45 PM EDT - 1 year ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 14, 2024, 6:21 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 1 year ago

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 4:15 PM EDT - 1 year ago

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

Mar 6, 2024, 9:48 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Mar 1, 2024, 7:30 AM EST - 1 year ago

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Feb 26, 2024, 4:15 PM EST - 1 year ago

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Jan 18, 2024, 8:30 AM EST - 2 years ago

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

bobmoney Dec. 25 at 2:44 PM

$TLPH Talphera's late Phase 3 underway at some of the Best medical sites in the USA... stay tuned... TLPH's Niyad would be the 1st FDA approved...

0 · Reply

LettuceLeverage Dec. 25 at 9:34 AM

$TLPH Risk premia compress only when proof accumulates, with macro volatility magnifying operational missteps. Momentum turns durable only after multiple confirmations.

0 · Reply

bobmoney Dec. 24 at 9:00 PM

$TLPH $10 plus if Niyad is FDA approved... my hope...

0 · Reply

bobmoney Dec. 24 at 9:00 PM

$TLPH Merry Christmas! May we see TLPH's Niyad FDA approved in 2026... & a stock price over $10... !

0 · Reply

Aawilliam2003 Dec. 24 at 7:56 PM

$TLPH if this gets acquired it will be for about $7. Run up to that

0 · Reply

bobmoney Dec. 24 at 4:03 PM

$TLPH Niyad needed in the USA ASAP...fact

0 · Reply

bobmoney Dec. 24 at 4:01 PM

$TLPH nazz...thinking to bet another 5,000 shares... think news any day... !

0 · Reply

bobmoney Dec. 24 at 3:26 PM

$TLPH look at OMER... FDA approval... believers won... :-) Niyad next up ? :-)))

0 · Reply

nazzangr Dec. 24 at 3:16 PM

0 · Reply

bobmoney Dec. 24 at 3:15 PM

$TLPH $CRMD happy holidays & Merry Christmas... CRMD & TLPH 2026 collaboration that will make (if Niyad is FDA approved in 2026) Niyad a game changer in Extracorporeal Circuit anticoagulant... !

0 · Reply

bobmoney Dec. 24 at 1:56 PM

$TLPH $CRMD my post was confusing... ... USA market revenue from heparin use in Extracorporeal Circuits (dialysis, heart...) was between 2.5 to 5 billion dollars in 2024... & we all know heparin has a 3 hour half-life (Niyad an 8 minute half-life)... !

0 · Reply

bobmoney Dec. 24 at 1:39 PM

$TLPH $CRMD If TLPH-CRMD's late Phase 3 Niyad is FDA approved... Niyad would be the --only & 1st FDA approved-- anticoagulant for kidney dialysis... USA Extracorporeal Circuits (kidney dialysis, open heart surgery, lungs)... in 2024 was valued at 2.5 to 5.0 billion dollars... !

0 · Reply

bobmoney Dec. 23 at 11:56 PM

$TLPH & CRMD... 2026...load up ;-))

0 · Reply

Greenday52 Dec. 23 at 11:04 PM

$TLPH

0 · Reply

bobmoney Dec. 23 at 8:48 PM

$TLPH $CRMD In 2024...5 billion dollars, the heparin Extracorporeal Circuits... heparin 3-hour half-life systemic bleeding... ...just think... TLPH-CRMD's Niyad an 8 minute half-life... !

2 · Reply

nazzangr Dec. 23 at 8:42 PM

$TLPH you are right we cant know that for sure, but been following this long enough…i want to be wrong believe me lol

0 · Reply

bobmoney Dec. 23 at 7:22 PM

$TLPH $CRMD TLPH some large Buys... TLPH one of the top biotech gainers, so far... !

0 · Reply

Yoda896 Dec. 23 at 6:46 PM

$TLPH We don't know that. Could be announced today, or early January, or whatever. At this point, we don't know anything. The only thing we can see is the stock performance, and it's saying phase III is ongoing. How fast? No way to tell. Also, it could go at turtle speed for now, and then suddenly jump to warm speed. Those big hospitals might start enrolling any day. When that happens, our luck may turn. I'm not saying I'm happy about this uncertainty. I'm not happy at all. But, that's the stock market. It's supposed to be unpredictable. Otherwise, everyone would bet everything on it.

0 · Reply

bobmoney Dec. 23 at 6:35 PM

$TLPH $CRMD TLPH now up -- 10 perecent on Volume -- CRMD upping their ownership in TLPH's by 20%...? !

0 · Reply

bobmoney Dec. 23 at 6:25 PM

$TLPH $CRMD TLPH -- breaking higher -- Niyad antivoagulant (NM active 8-minute half-life) superior likely to Heparin (systemic bleeding risk 3-hour half-life)... ""United States heparin market... extracorporeal circuits (like dialysis/surgery) was valued around 2.5 to 5 billion dollars in 2023-2024"" Why 1$ billion CRMD is now TLPH's largest shareholder (20% +/-)... & CRMD CEO Todisco is a lead (valuable) TLPH Board of Director... !

0 · Reply

Gencooliveoil Dec. 23 at 6:19 PM

$TLPH $CRMD

0 · Reply

bobmoney Dec. 23 at 6:09 PM

$TLPH $CRMD -- TLPH climbing --- Note below Revenue --"...30$ billion... (USA 39% of that)" Why 1$ billion market cap CRMD took a -- strategic position in TLPH -- & why CRMD CEO Todisco now a lead TLPH Board... Niyad 8-minute half-life likely a large % of the Heparin (3 hour half-life) anticoagulant market, note: "...anticoagulant in extracorporeal circuits (like dialysis, heart surgery)...projections reaching over 11$ billion (USA 39% of that total) by 2030 global and beyond..."

0 · Reply

Market Cap	51.74M
Revenue (ttm)	0.00
Net Income (ttm)	-13.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	44,000
Avg Vol	382,628
Day's Range	N/A - N/A
Shares Out	46.61M
Stochastic %K	42%
Beta	0.25
Analysts	Strong Sell
Price Target	$3.25